Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:31:06.533Z.
Calculation as of: 2026-10-06T17:31:06.533Z.
Quote observation: 2026-10-06T17:30:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bae8dd55c1776b4784265b7d6b815fecf0da21712464e51122872d0292d60ac3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$3.46B
EV/EBIT Ratio
N/A
TTM Avg
12.29x
3Y Avg
12.23x
5Y Avg
12.23x
Market Cap
$3.38B
EV/EBIT Ratio
35.58x
TTM Avg
33.32x
3Y Avg
35.69x
5Y Avg
35.69x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celcuity Inc. (CELC) | $3.46B | N/A | N/A | N/A | N/A |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.46B | N/A | 12.29x | 12.23x | 12.23x |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.46B | N/A | N/A | N/A | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.41B | N/A | N/A | N/A | N/A |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.52B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 35.58x | 33.32x | 35.69x | 35.69x |
| CareDx, Inc (CDNA)vs › | $3.38B | N/A | 18.58x | 18.58x | 18.58x |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | N/A | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.29B | N/A | N/A | N/A | N/A |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.70B | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
